ESMO 2020: After 3.5 Years, Pembrolizumab Continues to Demonstrate Benefits in High-Risk Stage III Melanoma
Overall survival results from EORTC 1325-MG/KEYNOTE-054 are still years away
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.